Last updated: 2026-10-06 22:07:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Outlook Therapeutics, Inc. (OTLK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.57, with a market capitalisation of $144.36M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.16 to $2.54. This page covers its latest market performance, valuation, price trends and company information.
$144.36M | |
$0.60 | |
$219.20 | |
$0.16 | |
$0.60 | |
3.12M | |
13.73M | |
-- | |
$2.54 | |
$0.16 | |
-- | |
-- |
Outlook Therapeutics, Inc. (OTLK) is trading at $0.58 in after-hours trading as of 2026-10-06 22:02:00, down 2.60% ($0.02) from the regular-session close of $0.60.
After-hours trading shows how investors are pricing OTLK after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Outlook Therapeutics, Inc. (OTLK) moved from $0.64 to $0.57, representing a decline of 10.56% ($0.07).
The stock traded between $0.53 and $0.67 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 5.72 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 17.3%
OTLK is currently trading at $0.57, placing it 17.3% of the way from its 52-week low of $0.16 to its 52-week high of $2.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Outlook Therapeutics, Inc. (OTLK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.